在製药、生物科技企业的药物研发阶段的联盟契约和条件 (2014？2020年)

本报告提供全球主要製药企业及生物科技企业，在药物研发阶段的联盟契约的缔结趋势的相关调查，契约概要和目的，支付条件，各契约、疾病、技术类型的联盟契约数量趋势，代表性案例 (案例研究)，相关企业的一览，契约的详细资讯 (共2000件以上)等资讯彙整，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 在药物研发阶段的化合物相关签订契约的理由

• 简介
• 在药物研发阶段的联盟所扮演的角色
  • 在药物研发阶段的引入授权
  • 在药物研发阶段的转出授权
• 在新药发现、前临床、临床阶段的交易的差异
• 药物研发阶段签订联盟契约的理由
  • 授权侧 (授权人) 签订药物研发阶段契约的理由
  • 授权取得侧 (被授权人) 签订药物研发阶段契约的理由
• 在药物研发阶段的联盟契约的未来性

第3章 在药物研发阶段的交易的策略与结构

• 简介
• 在哪个阶段各企业签订联盟契约？
  • 跟製药/生物科技企业的早期的联盟
  • 跟製药/生物科技企业的后期的联盟
• 在新药发现、前临床、临床阶段的联盟:风险/成本比较
• 在药物研发阶段的缔结的支出额
• 专门/复合契约的差异
• 专门授权合约结构
  • 代表性案例
• 多成分药物研发阶段合作伙伴契约
  • 在药物研发阶段的复合联盟契约
  • 代表性案例

第4章 在药物研发阶段的联盟的付款策略

• 简介
• 在药物研发阶段的付款策略
• 付款的选择

第5章 在药物研发阶段的契约缔结的趋势

• 简介
• 在药物研发阶段的契约缔结:近几年的趋势
  • 契约的特征
• 在药物研发阶段的联盟趋势:各交易类型
• 在药物研发阶段的联盟趋势:疾病的各类型
• 联盟趋势:药物研发阶段的各技术种类
• 在药物研发阶段的联盟趋势:最活跃的企业的情况 (2014年以后)

第6章 在药物研发阶段的联盟契约的付款条件

• 简介
• 在药物研发阶段的付款条件的指南
  • 预付款
  • 阶段性付款
  • 特许权支付
• 在药物研发阶段的付款条件:契约资料分析
  • 公共资料
  • 调查资料
• 付款条件分析
  • 在药物研发阶段的契约总额
  • 在药物研发阶段的预付款
  • 在药物研发阶段的阶段性付款
  • 在药物研发阶段的权利金费率

第7章 在药物研发阶段的主要契约

• 简介
• 在药物研发阶段的主要契约:各金额

第8章 在药物研发阶段的最活跃的契约对方:前25名公司

• 简介
• 在药物研发阶段的最活跃的契约对方:前25名公司

第9章 在药物研发阶段的联盟契约的一览

• 简介
• 在药物研发阶段的联盟契约动向 (2014年以后)

第10章 在药物研发阶段的契约缔结:各临床实验阶段趋势

• 简介
• 各药物研发阶段的交易趋势

附录

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest discovery agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2016 including financial terms where available including over 3,900 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2016. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 25 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2016, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2016.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2016.

In addition, a comprehensive appendix of all discovery deals since 2016 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Key benefits

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 provide the reader with the following key benefits:

• In-depth understanding of discovery stage deal trends since 2016
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of discovery stage agreements with numerous real life case studies
• Insight into the terms included in a discovery stage agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 include:

• Trends in discovery stage dealmaking in the biopharma industry since 2016
• Analysis of discovery stage deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life discovery stage deals
• Access to over 3,900 discovery stage deals
• The leading discovery stage deals by value since 2016
• Most active discovery stage dealmakers since 2016
• The leading discovery stage partnering 2016

In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal type
• Specific therapy target
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive access to available deals and contract documents for over 3,900 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides the reader with the following key benefits:

• In-depth understanding of discovery stage deal trends since 2016
• Access to headline, upfront, milestone and royalty data
• Comprehensive access to over 3,900 discovery stage deals together with contract documents if available
• Detailed access to actual discovery stage deals entered into by the leading 25 big pharma and big biotech companies along with other biopharma companies
• Analysis of the structure of discovery stage agreements with numerous real life case studies
• Identify leading discovery stage deals by value since 2016
• Identify the most active discovery stage dealmakers since 2016
• Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

• 2.1. Introduction
• 2.2. The role of discovery stage partnering
  • 2.2.1. In-licensing at discovery stage
  • 2.2.2. Out-licensing at discovery stage
• 2.3. Difference between discovery, preclinical and clinical stage deals
• 2.4. Reasons for entering into discovery stage partnering deals
  • 2.4.1. Licensors reasons for entering discovery stage deals
  • 2.4.2. Licensees reasons for entering discovery stage deals
• 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

• 3.1. Introduction
• 3.2. At what stage do companies partner?
  • 3.2.1. Partnering early in pharmaceutical/biotech
  • 3.2.1.1. Discovery and preclinical stage partnering case studies
  • 3.2.1.1.a. Case study 1
  • 3.2.1.1.b. Case study 2
  • 3.2.1.1.c. Case study 3
  • 3.2.1.1.d. Case study 4
  • 3.2.2. Partnering later in pharmaceutical/biotech
  • 3.2.2.1. Clinical stage partnering case studies
  • 3.2.2.1.a. Case study 5
  • 3.2.2.1.b. Case study 6
  • 3.2.2.1.c. Case study 7
  • 3.2.2.1.d. Case study 8
• 3.3. Early and later stage partnering - a risk/cost comparison
• 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
• 3.5. Pure versus multi-component partnering deals
• 3.6. Pure licensing agreement structure
  • 3.6.1. Example pure licensing agreements
  • 3.6.1.a. Case study 9
  • 3.6.1.b. Case study 10
• 3.7. Multicomponent discovery stage partnering agreements
  • 3.7.1.a. Example multicomponent early stage clauses
  • 3.7.1.a. Case study 11
  • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

• 4.1. Introduction
• 4.2. Discovery stage payment strategies
• 4.3. Payment options
  • 4.3.1. Headline values
  • 4.3.2. Upfront payments
  • 4.3.2.1. Conditionality of upfront payments
  • 4.3.3. Loans
  • 4.3.4. Convertible loans
  • 4.3.5. Equity
  • 4.3.6. R&D funding
  • 4.3.7. Licensing fees
  • 4.3.8. Milestone payments
  • 4.3.9. Royalty payments
  • 4.3.9.1. Issues affecting royalty rates
  • 4.3.9.2. Royalties on combination products
  • 4.3.9.2.a. Case study 13
  • 4.3.9.3. Guaranteed minimum/maximum annual payments
  • 4.3.9.4. Royalty stacking
  • 4.3.9.5. Royalties and supply/purchase contracts
  • 4.3.10. Quids
  • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

• 5.1. Introduction
• 5.2. Discovery stage partnering over the years
  • 5.2.1. Attributes of discovery deals
• 5.3. Discovery stage partnering by deal type
• 5.4. Discovery stage partnering by disease type
• 5.5. Partnering by discovery stage technology type
• 5.6. Discovery stage partnering by most active company, 2016 to 2023

Chapter 6 - Payment terms for discovery stage partnering

• 6.1. Introduction
• 6.2. Guidelines for discovery stage payment terms
  • 6.2.1. Upfront payments
  • 6.2.2. Milestone payments
  • 6.2.3. Royalty payments
• 6.3. Discovery stage payment terms - deal data analysis
  • 6.3.1. Public data
  • 6.3.2. Survey data
• 6.4. Payment terms analysis
  • 6.4.1. Discovery stage headline values
  • 6.4.2. Discovery stage deal upfront payments
  • 6.4.3. Discovery stage deal milestone payments
  • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

• 7.1. Introduction
• 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

• 8.1. Introduction
• 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

• 9.1. Introduction
• 9.2. Discovery stage deals with contracts 2016 to 2023

Chapter 10 - Discovery stage deal making by development stage

• 10.1. Introduction
• 10.2. Deals by discovery stage

Appendices

• Appendix 1 - Discovery stage dealmaking by companies A-Z
• Appendix 2 - Discovery stage dealmaking by industry sector
• Appendix 3 - Discovery stage dealmaking by stage of development
• Appendix 4 - Discovery stage dealmaking by therapy area
• Appendix 5 - Discovery stage dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from CurrentPartnering

Table of figures

• Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
• Figure 3: Components of the pure licensing deal structure
• Figure 4: Payment options for discovery stage partnering deals
• Figure 5: Issues affecting royalty rates
• Figure 6: Discovery stage partnering frequency 2016- 2023
• Figure 7: Discovery stage partnering by deal type since 2016
• Figure 8: Discovery stage partnering by disease type since 2016
• Figure 9: Discovery stage partnering by technology type since 2016
• Figure 10: Top 25 most active discovery stage dealmakers, 2016 to 2023
• Figure 11: Review of median upfront payments for discovery stage deals
• Figure 12: Review of median milestone payments for discovery stage deals
• Figure 13: Review of median royalty payments for discovery stage deals
• Figure 14: Discovery stage deals with a headline value
• Figure 15: Discovery stage deals with an upfront value
• Figure 16: Discovery stage deals with a milestone value
• Figure 17: Discovery stage deals with a royalty rate value
• Figure 18: Top discovery stage deals by deal value since 2016
• Figure 19: Most active discovery stage dealmakers 2016 to 2023